For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Biomarin Pharmaceutical Inc (NASDAQ: BMRN) closed at $56.56 in the last session, down -1.27% from day before closing price of $57.29. In other words, the price has decreased by -$1.27 from its previous closing price. On the day, 1.06 million shares were traded. BMRN stock price reached its highest trading level at $57.535 during the session, while it also had its lowest trading level at $56.5.
Ratios:
We take a closer look at BMRN’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.53 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.38. For the most recent quarter (mrq), Quick Ratio is recorded 3.49 and its Current Ratio is at 5.52. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
On February 24, 2025, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $98.
On November 15, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $95.Wolfe Research initiated its Outperform rating on November 15, 2024, with a $95 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 20 ’25 when Burkhart Erin sold 1,786 shares for $59.31 per share. The transaction valued at 105,928 led to the insider holds 14,173 shares of the business.
Burkhart Erin bought 1,786 shares of BMRN for $105,928 on May 20 ’25. On May 02 ’25, another insider, Hubbard Cristin, who serves as the EVP, Chief Commercial Officer of the company, sold 273 shares for $64.92 each. As a result, the insider received 17,723 and left with 32,700 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMRN now has a Market Capitalization of 10846851072 and an Enterprise Value of 9871532032. As of this moment, Biomarin’s Price-to-Earnings (P/E) ratio for their current fiscal year is 20.99, and their Forward P/E ratio for the next fiscal year is 13.39. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.62. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.71 while its Price-to-Book (P/B) ratio in mrq is 1.87. Its current Enterprise Value per Revenue stands at 3.346 whereas that against EBITDA is 12.238.
Stock Price History:
The Beta on a monthly basis for BMRN is 0.18, which has changed by -0.3284492 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, BMRN has reached a high of $94.85, while it has fallen to a 52-week low of $52.93. The 50-Day Moving Average of the stock is -1.33%, while the 200-Day Moving Average is calculated to be -11.50%.
Shares Statistics:
According to the various share statistics, BMRN traded on average about 2.08M shares per day over the past 3-months and 1822830 shares per day over the past 10 days. A total of 191.76M shares are outstanding, with a floating share count of 189.06M. Insiders hold about 1.42% of the company’s shares, while institutions hold 98.64% stake in the company. Shares short for BMRN as of 1749772800 were 4417385 with a Short Ratio of 3.14, compared to 1747267200 on 4449835. Therefore, it implies a Short% of Shares Outstanding of 4417385 and a Short% of Float of 2.9499999999999997.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Biomarin Pharmaceutical Inc (BMRN) is presently subject to a detailed evaluation by 20.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $1.04, with high estimates of $1.29 and low estimates of $0.51.
Analysts are recommending an EPS of between $4.59 and $3.84 for the fiscal current year, implying an average EPS of $4.31. EPS for the following year is $5.4, with 22.0 analysts recommending between $6.46 and $4.47.
Revenue Estimates
According to 21 analysts, the current quarter’s revenue is expected to be $761.51M. It ranges from a high estimate of $778M to a low estimate of $741M. As of the current estimate, Biomarin Pharmaceutical Inc’s year-ago sales were $712.03MFor the next quarter, 21 analysts are estimating revenue of $798.31M. There is a high estimate of $848.1M for the next quarter, whereas the lowest estimate is $746.1M.
A total of 27 analysts have provided revenue estimates for BMRN’s current fiscal year. The highest revenue estimate was $3.2B, while the lowest revenue estimate was $3.09B, resulting in an average revenue estimate of $3.14B. In the same quarter a year ago, actual revenue was $2.85BBased on 26 analysts’ estimates, the company’s revenue will be $3.45B in the next fiscal year. The high estimate is $3.7B and the low estimate is $3.2B.
